ECSP13012476A - Vacunas de virus varicela zóster inactivado, métodos de producción y uso de las mismas - Google Patents
Vacunas de virus varicela zóster inactivado, métodos de producción y uso de las mismasInfo
- Publication number
- ECSP13012476A ECSP13012476A ECSP13012476A ECSP13012476A EC SP13012476 A ECSP13012476 A EC SP13012476A EC SP13012476 A ECSP13012476 A EC SP13012476A EC SP13012476 A ECSP13012476 A EC SP13012476A
- Authority
- EC
- Ecuador
- Prior art keywords
- vzv
- inactivated
- virus
- zacster
- varicela
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 4
- 241000700605 Viruses Species 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 abstract 11
- 238000000034 method Methods 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- 230000007420 reactivation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/25—Varicella-zoster virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16761—Methods of inactivation or attenuation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
RESUMEN DE LA DESCRIPCIÓN La invención proporciona un virus varicela zóster (VVZ) inactivado, y composiciones y vacunas que comprenden dicho VVZ inactivado, donde la infectividad del VVZ es indetectable y donde el VVZ inactivado induce una respuesta inmune contra VVZ cuando se administra a un paciente. En realizaciones de las composiciones descritas en el presente documento, el VVZ se inactiva con radiación gamma. La invención también proporciona un método para preparar una vacuna de VVZ inactivado, comprendiendo el método someter a irradiación gamma una muestra que comprende VVZ usando de aproximadamente 5 kGy a aproximadamente 50 kGy de irradiación gama. También se proporciona por la invención del presente documento un método de tratamiento o de inmunización contra HZ u otra enfermedad asociada con la reactivación de VVZ, comprendiendo el método administrar a un sujeto una vacuna o composición farmacéutica que comprende una cantidad terapéuticamente eficaz de un VVZ inactivado y un vehículo farmacéuticamente aceptable, donde el VVZ se inactiva por irradiación gamma.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37103810P | 2010-08-05 | 2010-08-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP13012476A true ECSP13012476A (es) | 2013-04-30 |
Family
ID=45556327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP13012476 ECSP13012476A (es) | 2010-08-05 | 2013-03-04 | Vacunas de virus varicela zóster inactivado, métodos de producción y uso de las mismas |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US20120034267A1 (es) |
| EP (2) | EP3363894A1 (es) |
| JP (2) | JP2013535488A (es) |
| KR (3) | KR20160060790A (es) |
| CN (1) | CN103167880B (es) |
| AR (1) | AR082577A1 (es) |
| AU (1) | AU2011285749B2 (es) |
| BR (1) | BR112013001946A2 (es) |
| CA (1) | CA2806454A1 (es) |
| CL (2) | CL2013000360A1 (es) |
| CO (1) | CO6731067A2 (es) |
| EC (1) | ECSP13012476A (es) |
| MX (1) | MX343600B (es) |
| MY (1) | MY158419A (es) |
| NZ (1) | NZ606549A (es) |
| PE (1) | PE20131336A1 (es) |
| PH (1) | PH12013500133A1 (es) |
| RU (1) | RU2633058C2 (es) |
| SG (1) | SG187222A1 (es) |
| TW (1) | TW201208698A (es) |
| UA (1) | UA112970C2 (es) |
| WO (1) | WO2012018973A1 (es) |
| ZA (1) | ZA201300622B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015034807A2 (en) | 2013-09-05 | 2015-03-12 | Merck Sharp & Dohme Corp. | Methods of immunization with varicella zoster virus antigen |
| RU2651040C2 (ru) * | 2016-08-08 | 2018-04-18 | Федеральное государственное бюджетное учреждение "48 Центральный научно-исследовательский институт" Министерства обороны Российской Федерации | Вакцина оспенная инактивированная эмбриональная сухая таблетированная для орального применения "ТЭОВин" и способ ее получения |
| RU2637093C1 (ru) * | 2016-12-20 | 2017-11-29 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова" (ФГБНУ НИИВС им. И.И. Мечникова) | Способ получения живой культуральной аттенуированной вакцины для профилактики ветряной оспы |
| CN107174658B (zh) * | 2017-04-29 | 2020-11-27 | 安徽智飞龙科马生物制药有限公司 | 人用水痘病毒灭活疫苗及其制备方法 |
| CN109453371A (zh) * | 2018-11-23 | 2019-03-12 | 中国兽医药品监察所 | 一种羊痘、山羊传染性胸膜肺炎二联灭活疫苗及其生产方法 |
| RU2700410C1 (ru) * | 2019-05-20 | 2019-09-17 | Федеральное государственное бюджетное учреждение науки "Национальный научный центр морской биологии им. А.В. Жирмунского" Дальневосточного отделения Российской академии наук (ННЦМБ ДВО РАН) | Метод иммуноокрашивания биологического материала для конфокальной микроскопии |
| WO2021122507A1 (en) | 2019-12-16 | 2021-06-24 | Intervet International B.V. | Inactivated piscine orthoreovirus vaccine |
| WO2024191324A1 (ru) * | 2023-03-13 | 2024-09-19 | Олег Александрович ШИЛОВ | Способ получения препарата вакцины из цельных вирусов или бактерий |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5341202B2 (es) | 1974-03-12 | 1978-11-01 | ||
| DE2714665A1 (de) * | 1977-04-01 | 1978-10-05 | Mayr Anton | Praeparat zur behandlung von herpes zoster und anderen herpes-infektionen, sowie verfahren zu seiner herstellung |
| PT651789E (pt) | 1992-07-17 | 2002-05-31 | Merck & Co Inc | Metodo para a prevencao de zoster ou alivio de neuralgia pos-herpetica relacionada com varicela |
| US6022876A (en) * | 1996-11-15 | 2000-02-08 | Yale University | L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections |
| GB9921146D0 (en) * | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
| EP1286706A2 (en) * | 2000-05-17 | 2003-03-05 | The American National Red Cross | Gamma irradiation of protein-based pharmaceutical products |
| US6946098B2 (en) * | 2001-08-10 | 2005-09-20 | Clearant, Inc. | Methods for sterilizing biological materials |
| US20050175630A1 (en) * | 2003-12-23 | 2005-08-11 | Eyal Raz | Immunogenic compositions and methods of use thereof |
| CA2558586A1 (en) * | 2004-03-05 | 2005-09-15 | The Research Foundation For Microbial Diseases Of Osaka University | Recombinant varicella-zoster virus |
| GB0504436D0 (en) * | 2005-03-03 | 2005-04-06 | Glaxosmithkline Biolog Sa | Vaccine |
| RU2011107757A (ru) | 2008-08-01 | 2012-09-10 | Гамма Ваксинс Пти Лимитед (Au) | Вакцины против гриппа |
-
2011
- 2011-04-08 UA UAA201302742A patent/UA112970C2/uk unknown
- 2011-08-04 NZ NZ606549A patent/NZ606549A/en not_active IP Right Cessation
- 2011-08-04 MX MX2013001434A patent/MX343600B/es active IP Right Grant
- 2011-08-04 SG SG2013006515A patent/SG187222A1/en unknown
- 2011-08-04 CA CA2806454A patent/CA2806454A1/en not_active Abandoned
- 2011-08-04 KR KR1020167013241A patent/KR20160060790A/ko not_active Ceased
- 2011-08-04 EP EP18160689.8A patent/EP3363894A1/en not_active Withdrawn
- 2011-08-04 KR KR1020137002903A patent/KR20130036062A/ko not_active Ceased
- 2011-08-04 US US13/198,191 patent/US20120034267A1/en not_active Abandoned
- 2011-08-04 JP JP2013523327A patent/JP2013535488A/ja active Pending
- 2011-08-04 RU RU2013109417A patent/RU2633058C2/ru not_active IP Right Cessation
- 2011-08-04 PH PH1/2013/500133A patent/PH12013500133A1/en unknown
- 2011-08-04 PE PE2013000202A patent/PE20131336A1/es not_active Application Discontinuation
- 2011-08-04 MY MYPI2013000290A patent/MY158419A/en unknown
- 2011-08-04 KR KR1020167002433A patent/KR20160018828A/ko not_active Ceased
- 2011-08-04 BR BR112013001946A patent/BR112013001946A2/pt not_active IP Right Cessation
- 2011-08-04 TW TW100127807A patent/TW201208698A/zh unknown
- 2011-08-04 AU AU2011285749A patent/AU2011285749B2/en not_active Ceased
- 2011-08-04 CN CN201180046512.6A patent/CN103167880B/zh not_active Expired - Fee Related
- 2011-08-04 EP EP11815299.0A patent/EP2600893A4/en not_active Ceased
- 2011-08-04 WO PCT/US2011/046534 patent/WO2012018973A1/en not_active Ceased
- 2011-08-05 AR ARP110102849A patent/AR082577A1/es unknown
-
2013
- 2013-01-23 ZA ZA2013/00622A patent/ZA201300622B/en unknown
- 2013-02-01 CO CO13019546A patent/CO6731067A2/es unknown
- 2013-02-05 CL CL2013000360A patent/CL2013000360A1/es unknown
- 2013-03-04 EC ECSP13012476 patent/ECSP13012476A/es unknown
-
2015
- 2015-04-03 US US14/678,542 patent/US20150209424A1/en not_active Abandoned
- 2015-10-02 JP JP2015196551A patent/JP2016053032A/ja active Pending
-
2016
- 2016-12-12 CL CL2016003181A patent/CL2016003181A1/es unknown
-
2018
- 2018-07-03 US US16/026,779 patent/US20180318412A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6731067A2 (es) | Vacunas de virus varicela zoster inactivado, métodos de producción y uso de las mismas | |
| MX374287B (es) | Formulacion que contiene virus y uso de la misma. | |
| ECSP14005678A (es) | Composiciones y métodos para tratar el virus de la hepatitis c | |
| BR112018017307A2 (pt) | molécula de ácido nucleico isolada, composição, e, métodos para indução de uma resposta imune contra um zika vírus, para tratamento de um indivíduo e para prevenção de uma infecção por zika vírus | |
| Del Giudice et al. | Vaccines for the elderly | |
| KR20140033171A (ko) | 비활성화된 뎅기 바이러스 백신 | |
| NZ606993A (en) | Combination pharmaceutical composition and methods of treating and preventing the infectious diseases | |
| Garçon et al. | Development and evaluation of AS04, a novel and improved adjuvant system containing MPL and aluminum salt | |
| JP2015531389A5 (es) | ||
| BR112016002354A2 (pt) | composição imunogênica, métodos para proteger um bebê contra infecção ou doença e para evocar uma resposta imune, regime de vacinação, e, kit | |
| PE20110327A1 (es) | Vacuna contra el virus de papiloma humano | |
| DiStefano et al. | Immunogenicity of a reduced-dose whole killed rabies vaccine is significantly enhanced by ISCOMATRIX™ adjuvant, Merck amorphous aluminum hydroxylphosphate sulfate (MAA) or a synthetic TLR9 agonist in rhesus macaques | |
| EA201690057A1 (ru) | Остеопонтин молока млекопитающих для повышения иммунологической реактивности | |
| BR112013006515A2 (pt) | vacina de combinação, e, método para a fabricação de uma vacina de combinação | |
| WO2010129947A3 (en) | Alpha thymosin peptides as vaccine enhancers | |
| BR112014027885A2 (pt) | produção de ingredientes farmacêuticos ativos estéreis | |
| Verma et al. | Intra-dermal administration of rabies vaccines in developing countries: at an affordable cost | |
| Kim et al. | Virus-like particles presenting flagellin exhibit unique adjuvant effects on eliciting T helper type 1 humoral and cellular immune responses to poor immunogenic influenza virus M2e protein vaccine | |
| Adam et al. | VSA-2-, a novel plant-derived adjuvant for SARS-CoV-2 subunit vaccine | |
| WO2015034807A3 (en) | Methods of immunization with varicella zoster virus antigen | |
| MX2009011312A (es) | Regimen de vacunacion para vacunas de celulas b. | |
| UY38933A (es) | Vacuna de partículas tipo virus del chicunguña y métodos para su uso | |
| Lemmer et al. | Protective efficacy of a plant-produced beta variant rSARS-CoV-2 VLP vaccine in golden Syrian hamsters | |
| AR070368A2 (es) | Procedimiento para la preparacion de una composicion de vacuna que comprende un inmunoestimulante un antigeno y una sal metalica y uso de dicha composicion para preparar un medicamento.composicion de vacuna | |
| AR103030A1 (es) | Composición inmunógena |